1. Contemporary Therapy of Femoropopliteal In-Stent Restenosis / Occlusion, 36-month Follow up Study.
- Author
-
Suzuki K, Takahara M, Tobita K, Hayakawa N, Mori S, Iwata Y, Horie K, and Nakama T
- Subjects
- Humans, Male, Retrospective Studies, Female, Aged, Time Factors, Treatment Outcome, Japan, Risk Factors, Middle Aged, Aged, 80 and over, Alloys, Vascular Access Devices, Constriction, Pathologic, Follow-Up Studies, Femoral Artery physiopathology, Femoral Artery diagnostic imaging, Popliteal Artery physiopathology, Popliteal Artery diagnostic imaging, Peripheral Arterial Disease therapy, Peripheral Arterial Disease physiopathology, Peripheral Arterial Disease diagnostic imaging, Vascular Patency, Angioplasty, Balloon instrumentation, Angioplasty, Balloon adverse effects, Recurrence, Drug-Eluting Stents, Prosthesis Design, Coated Materials, Biocompatible, Stents
- Abstract
Background: Drug-eluting devices improved outcomes of endovascular therapy (EVT) for femoropopliteal lesions, but mainly for de novo lesions. Endovascular therapy for in-stent restenosis/occlusion (ISR/O) is challenging, and large trials and long-term data are not well reported., Materials and Methods: This study is a physician initiated, multicenter, and retrospective design. From 7 Japanese institutes, 3635 femoropopliteal cases were enrolled in the study. Among these, 346 cases of first ISR/O were studied. We defined drug-coated-balloon, drug-eluting stent, and covered stent as New devices. Balloon angioplasty and bare nitinol stent were included in the control group., Results: The propensity score matching extracted 112 pairs. At 12 months, the primary patency rate was 80.3% in the new device group and 52.7% in the control group, and there was a significant intergroup difference ( P = .004). However, at 36 months, the rate was 43.3% vs 39.2%, with no significant difference ( P = .090). No baseline characteristics had any significant interaction effect (all P > .05)., Conclusions: The New devices were more effective than the control group for ISR/O at 1 year, but caught up at 3 years., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Kenji Suzuki had a payment for lectures from Boston Scientific Japan, Japan GORE, Kaneka, Cook Medical, Cordis, and Bayer. Mitsuyoshi Takahara had a payment for lectures from Japan GORE, Boston Scientific Japan, and TERUMO. Kazuki Tobita had a payment for lectures from Medtronic, TERUMO, BD, and Kaneka, and had a consulting fees from Japan GORE. Naoki Hayakawa had a payment for lectures from Boston Scientific Japan, TERUMO, Kaneka, Medtronic, and Medicos Hirata. Yo Iwata had a payment for lectures from Boston Scientific Japan, Cook, and Philips Japan. Tatsuya Nakama had a payment for lectures from Boston Scientific Japan, Medtronic, Cook, TERUMO, Abbott Vascular, and Becton Dickinson and Company, had a consulting fee from Boston Scientific Japan, Medtronic, Cook, Century Medical, Cordis, OrbusNeichi, and Becton Dickinson and Company, had a payment for expert testimony from NIPRO, Kaneka, and Asahi Intecc.
- Published
- 2024
- Full Text
- View/download PDF